These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18052314)

  • 1. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
    Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
    J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
    Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
    J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.
    Tsotinis A; Vlachou M; Papahatjis DP; Calogeropoulou T; Nikas SP; Garratt PJ; Piccio V; Vonhoff S; Davidson K; Teh MT; Sugden D
    J Med Chem; 2006 Jun; 49(12):3509-19. PubMed ID: 16759094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation.
    Elsner J; Boeckler F; Davidson K; Sugden D; Gmeiner P
    Bioorg Med Chem; 2006 Mar; 14(6):1949-58. PubMed ID: 16290939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (R)-2-(4-Phenylbutyl)dihydrobenzofuran derivatives as melatoninergic agents.
    Sun LQ; Takaki K; Chen J; Bertenshaw S; Iben L; Mahle CD; Ryan E; Wu D; Gao Q; Xu C
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1345-9. PubMed ID: 15713384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
    Rivara S; Mor M; Silva C; Zuliani V; Vacondio F; Spadoni G; Bedini A; Tarzia G; Lucini V; Pannacci M; Fraschini F; Plazzi PV
    J Med Chem; 2003 Apr; 46(8):1429-39. PubMed ID: 12672242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Substituted anilides as selective melatonin MT2 receptor agonists.
    Epperson JR; Deskus JA; Gentile AJ; Iben LG; Ryan E; Sarbin NS
    Bioorg Med Chem Lett; 2004 Feb; 14(4):1023-6. PubMed ID: 15013015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors.
    Mathé-Allainmat M; Gaudy F; Sicsic S; Dangy-Caye AL; Shen S; Brémont B; Benatalah Z; Langlois M; Renard P; Delagrange P
    J Med Chem; 1996 Aug; 39(16):3089-95. PubMed ID: 8759629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New selective ligands of human cloned melatonin MT1 and MT2 receptors.
    Audinot V; Mailliet F; Lahaye-Brasseur C; Bonnaud A; Le Gall A; Amossé C; Dromaint S; Rodriguez M; Nagel N; Galizzi JP; Malpaux B; Guillaumet G; Lesieur D; Lefoulon F; Renard P; Delagrange P; Boutin JA
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):553-61. PubMed ID: 12764576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-intrinsic activity relationship studies in the group of 1-imido/amido substituted 4-(4-arylpiperazin-1-yl)cyclohexane derivatives; new, potent 5-HT1A receptor agents with anxiolytic- like activity.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Bugno R; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2006 Mar; 14(5):1391-402. PubMed ID: 16266808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors.
    Larraya C; Guillard J; Renard P; Audinot V; Boutin JA; Delagrange P; Bennejean C; Viaud-Massuard MC
    Eur J Med Chem; 2004 Jun; 39(6):515-26. PubMed ID: 15183910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability.
    Ferlenghi F; Mari M; Gobbi G; Elisi GM; Mor M; Rivara S; Vacondio F; Bartolucci S; Bedini A; Fanini F; Spadoni G
    ChemMedChem; 2021 Oct; 16(19):3071-3082. PubMed ID: 34213063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide: an orally bioavailable melatonin receptor agonist.
    Sun LQ; Takaki K; Chen J; Iben L; Knipe JO; Pajor L; Mahle CD; Ryan E; Xu C
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5157-60. PubMed ID: 15380218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding.
    Mazna P; Obsilova V; Jelinkova I; Balik A; Berka K; Sovova Z; Ettrich R; Svoboda P; Obsil T; Teisinger J
    J Neurochem; 2004 Nov; 91(4):836-42. PubMed ID: 15525337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue.
    Rivara S; Diamantini G; Di Giacomo B; Lamba D; Gatti G; Lucini V; Pannacci M; Mor M; Spadoni G; Tarzia G
    Bioorg Med Chem; 2006 May; 14(10):3383-91. PubMed ID: 16431121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers.
    Ayoub MA; Levoye A; Delagrange P; Jockers R
    Mol Pharmacol; 2004 Aug; 66(2):312-21. PubMed ID: 15266022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling.
    Frølund B; Jensen LS; Guandalini L; Canillo C; Vestergaard HT; Kristiansen U; Nielsen B; Stensbøl TB; Madsen C; Krogsgaard-Larsen P; Liljefors T
    J Med Chem; 2005 Jan; 48(2):427-39. PubMed ID: 15658856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel non-steroidal/non-anilide type androgen antagonists: discovery of 4-substituted pyrrole-2-carboxamides as a new scaffold for androgen receptor ligands.
    Wakabayashi K; Miyachi H; Hashimoto Y; Tanatani A
    Bioorg Med Chem; 2005 Apr; 13(8):2837-46. PubMed ID: 15781394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.